1. Home
  2. ATEC vs SNDX Comparison

ATEC vs SNDX Comparison

Compare ATEC & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alphatec Holdings Inc.

ATEC

Alphatec Holdings Inc.

N/A

Current Price

$10.72

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

N/A

Current Price

$16.87

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ATEC
SNDX
Founded
1990
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2006
2014

Fundamental Metrics

Financial Performance
Metric
ATEC
SNDX
Price
$10.72
$16.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
12
Target Price
$15.79
★ $37.55
AVG Volume (30 Days)
★ 2.3M
1.6M
Earning Date
10-29-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 15.04
11.56
EPS
★ N/A
N/A
Revenue
$101,739,000.00
★ $172,352,000.00
Revenue This Year
$15.43
$82.71
Revenue Next Year
$15.24
$45.79
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 627.84
52 Week Low
$6.82
$13.00
52 Week High
$23.29
$25.59

Technical Indicators

Market Signals
Indicator
ATEC
SNDX
Relative Strength Index (RSI) 58.70 36.00
Support Level $10.61 N/A
Resistance Level $11.03 $18.75
Average True Range (ATR) 0.39 0.75
MACD 0.01 -0.06
Stochastic Oscillator 80.71 19.22

Price Performance

Historical Comparison
ATEC
SNDX

About ATEC Alphatec Holdings Inc.

Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: